cilengitide has been researched along with deoxycytidine in 5 studies
| Studies (cilengitide) | Trials (cilengitide) | Recent Studies (post-2010) (cilengitide) | Studies (deoxycytidine) | Trials (deoxycytidine) | Recent Studies (post-2010) (deoxycytidine) |
|---|---|---|---|---|---|
| 194 | 29 | 133 | 18,160 | 4,652 | 8,898 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bier, J; Gath, HJ; Oettle, H; Raguse, JD; Riess, H | 1 |
| Balcke, P; Castellano, D; Davidson, N; Dittrich, C; Dobrowolski, F; Esteve, AA; Friess, H; Hawkins, R; Herzog, P; Hossfeld, DK; Katz, F; Kleeff, J; Kovar, A; Langrehr, JM; Neyns, B; Niedergethmann, M; Nippgen, J; Oettle, H; Piedbois, P; Raedle, J; Scheithauer, W; Stöger, H; Tempia-Caliera, AA; van Belle, S; Vermorken, J | 1 |
| Bridges, E; Harris, AL | 1 |
| Alrawashdeh, W; Cereser, B; Crnogorac-Jurcevic, T; Demircioglu, F; Elia, G; Ghazaly, E; Hagemann, T; Hodivala-Dilke, KM; Kocher, HM; McDonald, S; Scudamore, CL; Stratford, MR; Wong, PP | 1 |
| Atanackovic, D; Barlesi, F; Bennouna, J; Feurer, M; Germonpre, P; Goekkurt, E; Gridelli, C; Hicking, C; Krzakowski, M; Lena, H; Milanowski, J; O'Byrne, K; Picard, M; Schuette, W; Straub, J; Szczesna, A; Vansteenkiste, J; Verhoeven, D; Waller, CF | 1 |
2 trial(s) available for cilengitide and deoxycytidine
| Article | Year |
|---|---|
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.
Topics: Adult; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Snake Venoms; Surveys and Questionnaires; Survival Rate | 2006 |
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Integrin alphaVbeta3; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptors, Vitronectin; Snake Venoms; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
3 other study(ies) available for cilengitide and deoxycytidine
| Article | Year |
|---|---|
Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Facial Neoplasms; Gemcitabine; Humans; Jaw Neoplasms; Male; Middle Aged; Snake Venoms | 2004 |
Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Snake Venoms; Verapamil | 2015 |
Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Snake Venoms; Verapamil | 2015 |